Accendra Health Inc income statement
In fiscal 2025, Accendra Health Inc reported revenue of $2.76bn, up 3.1% on the year before, operating income of $27.5m (a 1.0% margin) and net income of −$1.10bn, or −$14.31 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,038 | 8,124 | 8,628 | 8,868 | 9,072 | 9,440 | 9,773 | 9,723 | 9,318 | 9,418 | 9,211 | 8,480 | 9,785 | 9,955 | 2,553 | 2,680 | 2,762 | 2,647 |
| Cost of revenue | — | — | — | — | — | — | — | 8,536 | 8,146 | 8,348 | 8,082 | 7,199 | 8,272 | 8,129 | 1,336 | 1,400 | 1,473 | 1,460 |
| Gross profit | 814 | 808 | 858 | 925 | 1,117 | 1,170 | 1,215 | 1,187 | 1,172 | 1,071 | 1,128 | 1,281 | 1,513 | 1,826 | 2,125 | 2,219 | 1,289 | 1,187 |
| Research and development | — | — | — | — | — | — | — | — | — | — | — | — | 12 | 12 | 13 | 13 | — | — |
| Selling, general and administrative | 592 | 564 | 611 | 683 | 864 | 984 | 994 | 970 | 1,017 | 953 | 1,023 | 1,041 | 1,077 | 1,555 | 1,002 | 1,082 | 1,068 | 1,036 |
| Operating income | 201 | 196 | 204 | 197 | 198 | 160 | 200 | 200 | 89 | −352 | 73 | 204 | 368 | 143 | 133 | −218 | 27 | 29 |
| Interest expense | 13 | 14 | 14 | 13 | 13 | 18 | 27 | 27 | 32 | 71 | 98 | 83 | 48 | 129 | 117 | 108 | 107 | 124 |
| Income before tax | 188 | 182 | 190 | 183 | 185 | 126 | 173 | 173 | 57 | −427 | −29 | 110 | 277 | 11 | 15 | −330 | −102 | −115 |
| Income tax | 71 | 71 | 75 | 74 | 74 | 60 | 70 | 64 | −15 | −32 | −6 | 22 | 55 | −11 | 6 | 21 | 1 | −5 |
| Net income | 105 | 111 | 115 | 109 | 111 | 67 | 103 | 109 | 73 | −437 | −62 | 30 | 222 | 22 | −41 | −363 | −1,101 | −302 |
| Diluted EPS | $1.67 | $1.75 | $1.81 | $1.72 | $1.76 | $1.06 | $1.65 | $1.76 | $1.20 | −$7.28 | −$1.03 | $0.47 | $2.94 | $0.29 | −$0.53 | −$4.73 | −$14.31 | −$3.94 |
| Diluted shares (average) | 62m | 63m | 63m | 63m | 63m | 62m | 62m | 61m | 60m | 60m | 61m | 64m | 75m | 76m | 77m | 77m | 77m | 77m |
| EBITDA | 227 | 225 | 238 | 236 | 249 | 223 | 266 | 255 | 149 | −250 | 190 | 297 | 459 | 372 | 344 | −36 | 242 | 285 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 687 | 695 | 674 | 682 | 697 | 709 | 628 | 613 |
| Cost of revenue | 355 | 362 | 355 | 357 | 375 | 386 | 350 | 350 |
| Gross profit | 560 | 580 | 526 | 325 | 322 | 323 | 278 | 263 |
| Selling, general and administrative | 272 | 270 | 262 | 268 | 266 | 271 | 255 | 244 |
| Operating income | 31 | −273 | 20 | −40 | 26 | 21 | 17 | −35 |
| Interest expense | 29 | 28 | 34 | 26 | 29 | 28 | 32 | 35 |
| Income before tax | 1 | −302 | −5 | −85 | −4 | −8 | −16 | −88 |
| Income tax | −0 | 30 | −2 | −1 | 2 | 1 | −10 | 1 |
| Net income | −13 | −296 | −25 | −869 | −150 | −56 | −6 | −89 |
| Diluted EPS | −$0.16 | −$3.86 | −$0.32 | −$11.30 | −$1.94 | −$0.76 | −$0.08 | −$1.16 |
| EBITDA | 93 | −291 | 63 | 3 | 125 | 51 | 79 | 31 |
Compare with peers
- 111, Inc. income statement
- Henry Schein income statement
- Cosmos Health Inc. income statement
- Cencora income statement
- McKesson income statement
Head to head: ACH vs YIACH vs HSICACH vs COSM
More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies